<DOC>
	<DOCNO>NCT00720109</DOCNO>
	<brief_summary>This phase II/III trial study side effect well give dasatinib together combination chemotherapy work treat young patient newly diagnose acute lymphoblastic leukemia ( ALL ) . Dasatinib may stop growth cancer cell block enzymes need cell growth . Drugs use chemotherapy work different way stop growth cancer cell , either kill cell stop divide . Giving dasatinib together combination chemotherapy may kill cancer cell .</brief_summary>
	<brief_title>Dasatinib Combination Chemotherapy Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine feasibility toxicity intensify chemotherapeutic regimen incorporate dasatinib treatment child , adolescent , young adult ( age 30 ) Philadelphia chromosome positive ( Ph+ ) acute lymphoblastic leukemia ( ALL ) . II . To determine whether intensification tyrosine kinase inhibition addition dasatinib Induction ( Days 15-28 ) substitution dasatinib imatinib post-Induction therapy , context intensive cytotoxic therapy ( accord AALL0031 ) good early response therapy , lead 3-year event-free survival ( EFS ) least 60 % patient Ph+ ALL . SECONDARY OBJECTIVES : I . To determine whether addition dasatinib Induction therapy ( Days 15-28 ) decrease level minimal residual disease ( MRD ) present end Induction therapy compare COG AALL0031 . II . To determine whether early intensify tyrosine kinase inhibitor ( TKI ) therapy lower end-Consolidation MRD level compare patient COG AALL0031 receive imatinib Consolidation Blocks 1 2 ( Cohorts 3-5 ) . III . To determine overall 3-year EFS rate whole cohort Standard- High-Risk patient treat dasatinib . IV . To determine long-term effect dasatinib growth , development , bone metabolism . V. To assess BCR-ABL mutation status time diagnosis progression/relapse . OUTLINE : This multicenter study . Patients stratify accord risk ( standard risk v high risk ) end consolidation therapy . INDUCTION THERAPY ( week 1-4 ) : Patients receive initial induction therapy day 1-14 prior beginning study . Patients receive vincristine intravenously ( IV ) daunorubicin hydrochloride* IV 15 minute day 15 22 ; dasatinib orally ( PO ) daily ( QD ) prednisone PO ( methylprednisolone IV ) twice daily ( BID ) day 15-28 ; methotrexate intrathecally ( IT ) day 29 ; patient receive methotrexate , hydrocortisone , cytarabine IT day 15 22 . After completion induction therapy , patient undergo bone marrow aspiration evaluation disease . Patients M1 bone marrow minimal residual disease ( MRD ) &lt; 1 % ( standard-risk disease ) proceed block 1 consolidation therapy 1 week completion induction therapy blood count recover ( whichever occurs later ) . Patients M2 M3 bone marrow MRD &gt; = 1 % ( high-risk disease ) proceed immediately block 1 consolidation therapy , regardless blood count . Patients clinically evident biopsy-proven testicular leukemia diagnosis persist end induction therapy undergo 12 fraction testicular radiotherapy begin within 4 day prior start block 1 consolidation therapy . NOTE : *Patients receive initial induction therapy DFCI Childhood ALL Consortium trial receive daunorubicin hydrochloride induction therapy study . CONSOLIDATION THERAPY : BLOCK 1 CONSOLIDATION THERAPY : ( week 6-8 ) Patients receive etoposide IV 1 hour ifosfamide IV 1 hour day 1-5 , dasatinib PO day 1-14 OR day 1-21 , patient receive methotrexate , hydrocortisone , cytarabine IT day 8 15 . Patients also receive filgrastim ( G-CSF ) subcutaneously ( SC ) IV QD begin day 6 continue blood count recover . After completion block 1 consolidation therapy , patient proceed block 2 consolidation therapy . BLOCK 2 CONSOLIDATION THERAPY : ( week 9-11 ) Patients receive high-dose methotrexate IV continuously 24 hour day 1 ; leucovorin calcium PO IV every 6 hour 3 dos day 2-3 ; methotrexate , hydrocortisone , cytarabine IT day 1 ; cytarabine IV 3 hour every 12 hour 4 dos day 2 3 ; dasatinib PO day 1-14 OR day 1-21 . Patients also receive G-CSF SC IV QD begin day 4 continue blood count recover . After completion block 2 consolidation therapy recovery blood count , patient undergo bone marrow aspiration evaluation disease . Patients MRD &lt; 0.01 % ( standard-risk disease ) match related donor willing undergo hematopoietic stem cell transplantation ( HSCT ) proceed HSCT study . Standard-risk patient without suitable donor elect undergo HSCT proceed post-consolidation therapy . Patients MRD &gt; = 0.01 % ( high-risk disease ) match related unrelated donor proceed HSCT study . High-risk patient without suitable donor proceed post-consolidation therapy . POST-CONSOLIDATION THERAPY : REINDUCTION BLOCK 1 THERAPY : ( week 12-14 ) Patients receive vincristine IV day 1 , 8 , 15 ; daunorubicin hydrochloride IV 15 minute day 1 2 ; cyclophosphamide IV 1 hour every 12 hour 4 dos day 3 4 ; pegaspargase intramuscularly ( IM ) day 4 ; methotrexate , hydrocortisone , cytarabine IT day 1 15 ; dexamethasone PO IV BID day 1-7 15-21 ; dasatinib PO day 1-14 OR day 1-21 . Patients also receive G-CSF SC IV QD begin day 5 continue blood count recover . After completion reinduction block 1 therapy , patient proceed intensification block 1 therapy . INTENSIFICATION BLOCK 1 THERAPY : ( week 15-23 ) Patients receive high-dose methotrexate IV continuously 24 hour day 1 ; leucovorin calcium PO IV every 6 hour 3 dos day 2-3 ; methotrexate , hydrocortisone , cytarabine IT day 1 22 ; etoposide IV 1 hour cyclophosphamide IV 1 hour day 22-26 ; cytarabine IV 3 hour every 12 hour 4 dos day 43 44 ; asparaginase IM day 44 ; dasatinib PO day 1-14 , 22-35 , 43-56 OR day 1-63 . Patients also receive G-CSF SC IV QD begin day 27 continue blood count recover . After completion intensification block 1 therapy , patient proceed reinduction block 2 therapy . REINDUCTION BLOCK 2 THERAPY : ( week 24-26 ) Patients receive reinduction block 2 therapy per reinduction block 1 therapy . After completion reinduction block 2 therapy , patient proceed intensification block 2 therapy . INTENSIFICATION BLOCK 2 THERAPY : ( week 27-35 ) Patients receive intensification block 2 therapy per intensification block 1 therapy . After completion intensification block 2 therapy , patient proceed maintenance therapy . MAINTENANCE THERAPY : MAINTENANCE COURSES 1-4 : ( week 36-67 ) Patients receive high-dose methotrexate IV continuously 24 hour day 1 ; leucovorin calcium PO IV every 6 hour 3 dos day 2-3 ; methotrexate , hydrocortisone , cytarabine IT vincristine IV day 1 29 ; prednisone PO IV BID day 1-5 29-33 ; mercaptopurine PO day 8-28 ; methotrexate PO day 8 , 15 , 22 ; etoposide IV 1 hour cyclophosphamide IV 1 hour day 29-33 ; dasatinib PO day 1-14 29-42 OR day 1-56 . Patients also receive G-CSF SC IV QD begin day 34 continue blood count recover . Courses repeat every 56 day . After completion maintenance course 1-4 , patient proceed maintenance course 5 . MAINTENANCE COURSE 5 : ( week 68-75 ) Patients receive vincristine IV day 1 29 ; prednisone PO IV BID maintenance course 6-12 . MAINTENANCE COURSES 6-12 : ( week 76-131 ) Patients receive vincristine IV day 1 29 ; prednisone PO IV BID day 1-5 29-33 ; mercaptopurine PO day 1-56 ; methotrexate PO day 1 , 8 , 15 , 22 , 29 , 36 , 43 , 50 ; dasatinib PO day 1-14 29-42 OR day 1-56 . Courses repeat every 56 day . Patients long-term growth , development , bone metabolism assess completion study therapy annually 5 year . After completion study therapy , patient follow periodically 10 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Cortisone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Cortisone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<mesh_term>Podophyllotoxin</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<criteria>Newly diagnose acute lymphoblastic leukemia ( ALL ) Definitive evidence BCRABL fusion ( Philadelphia chromosome positive [ PH+ ] ) approve Children 's Oncology Group ( COG ) cytogenetics laboratory Meets one follow criterion : Concurrent enrollment Clusters Orthologous Groups ( COG ) AALL03B1 ( successor trial ) AND COGAALL0232 , COGAALL0331 , COGAALL0434 frontline COG ALL clinical trial Concurrent enrollment COGAALL03B1 ( successor trial ) AND schedule receive 3 4drug standard induction regimen Concurrent enrollment DanaFarber Cancer Institute ( DFCI ) Childhood ALL Consortium trial ( schedule treat per DFCI Childhood ALL Consortium induction regimen ) All patient must definitive evidence BCRABL fusion approve COG cytogenetics laboratory ; patient may NOT receive Day 15 Induction chemotherapy ( day 18 vincristine enrol DFCI Childhood ALL Consortium trial ) prior enrollment AALL0622 Patients must performance status 0 , 1 2 completion two week Induction ; use Karnofsky patient &gt; 16 year age Lansky patient = &lt; 16 year age Creatinine clearance radioisotope glomerular filtration rate ( GFR ) &gt; = 70mL/min/1.73 m^2 maximum serum creatinine base age gender follow : 0.4 mg/dL ( patient 1 5 month age ) 0.5 mg/dL ( patient 6 11 month age ) 0.6 mg/dL ( patient 1 year age ) 0.8 mg/dL ( patient 2 5 year age ) 1.0 mg/dL ( patient 6 9 year age ) 1.2 mg/dL ( patient 10 12 year age ) 1.5 mg/dL ( male ) 1.4 mg/dL ( female ) ( patient 13 15 year age ) 1.7 mg/dL ( male ) 1.4 mg/dL ( female ) ( patient &gt; = 16 year age ) Total bilirubin = &lt; 1.5 time upper limit normal ( ULN ) age Serum glutamate pyruvate transaminase ( SGPT ) ( alanine aminotransferase [ ALT ] ) &lt; 2.5 time ULN age Shortening fraction &gt; = 27 % echocardiogram ejection fraction &gt; = 50 % gate radionuclide study No evidence dyspnea rest , exercise intolerance , pulse oximetry &gt; 94 % sea level clinical indication determination Patients seizure disorder may enrol anticonvulsant well control ; however , drug induce CYP3A4/5 ( carbamazepine , oxcarbazepine , phenytoin , primidone , phenobarbital ) avoid Patients start AALL0622 therapy day 15 induction therapy ( day 18 enrol DFCI Childhood ALL Consortium trial ) ; patient must receive first 2 week Induction therapy Females childbearing potential must negative pregnancy test ; patient childbearing potential must agree use effective birth control method Female patient lactate must agree stop breastfeeding Patients Down syndrome Patients clinically significant cardiovascular disease include follow : Myocardial infarction ventricular tachyarrhythmia within 6 month Ejection fraction less institutional normal Major conduction abnormality ( unless cardiac pacemaker present )</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>